Kentucky Retirement Systems Insurance Trust Fund Buys 1,870 Shares of Johnson & Johnson (NYSE:JNJ)

Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Johnson & Johnson (NYSE:JNJFree Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 85,761 shares of the company’s stock after buying an additional 1,870 shares during the period. Johnson & Johnson comprises 0.9% of Kentucky Retirement Systems Insurance Trust Fund’s portfolio, making the stock its 16th biggest holding. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Johnson & Johnson were worth $13,442,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 15,945,533 shares of the company’s stock worth $2,483,532,000 after purchasing an additional 241,799 shares in the last quarter. California Public Employees Retirement System raised its position in Johnson & Johnson by 4.9% in the fourth quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock worth $1,664,620,000 after purchasing an additional 498,647 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Johnson & Johnson by 10.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 10,169,190 shares of the company’s stock worth $1,593,908,000 after purchasing an additional 975,485 shares in the last quarter. Raymond James & Associates increased its holdings in shares of Johnson & Johnson by 0.4% during the fourth quarter. Raymond James & Associates now owns 6,061,707 shares of the company’s stock worth $950,112,000 after buying an additional 26,982 shares in the last quarter. Finally, Ninety One UK Ltd increased its holdings in shares of Johnson & Johnson by 0.3% during the fourth quarter. Ninety One UK Ltd now owns 4,436,013 shares of the company’s stock worth $695,301,000 after buying an additional 12,867 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Bank of America dropped their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a report on Thursday, May 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, May 6th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $175.86.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $151.32 on Tuesday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The stock has a market cap of $364.18 billion, a PE ratio of 9.43, a PEG ratio of 2.55 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm’s 50 day moving average price is $152.11 and its two-hundred day moving average price is $155.12.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.68 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.64 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.28%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 29.68%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.